نتائج البحث - "Johanna C. Bendell"

101

Abstract A167: First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology

المؤلفون: Brett E. Houk, Julian R. Molina, Geoffrey I. Shapiro, Eunice Kwak, Gary Borzillo, Josep Tabernero, Robert Millham, Katherine Bell-McGuinn, Johanna C. Bendell

المصدر: Molecular Cancer Therapeutics. 10:A167-A167

مصطلحات موضوعية: Volume of distribution, Cancer Research, education.field_of_study, business.industry, Population, Cancer, Pharmacology, medicine.disease, Rash, Oncology, Pharmacokinetics, Pharmacodynamics, medicine, Mucositis, medicine.symptom, education, business, PI3K/AKT/mTOR pathway

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::0ac1feeb07c15b38f695a7c9e62a4f1bTest
https://doi.org/10.1158/1535-7163.targ-11-a167Test

102

Abstract B56: A phase 1, open-label, dose escalation, nonrandomized study to assess the maximum tolerated dose, dose limiting toxicity, and pharmacokinetics of OPB-31121 in subjects with advanced solid tumors

المؤلفون: Gerald S. Falchook, David S. Hong, Agnes Elekes, Takumi Sumida, Suzanne F. Jones, Aung Naing, Masaaki Motoyama, Howard A. Burris, Shiva Patil, Jennifer A. Lee, Razelle Kurzrock, Patricia Bricmont, Johanna C. Bendell, Kodama Takeshi, Jeffrey R. Infante

المصدر: Molecular Cancer Therapeutics. 10:B56-B56

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Nausea, business.industry, Cancer, Pharmacology, medicine.disease, Gastroenterology, Oncology, Pharmacokinetics, Internal medicine, Hepatocellular carcinoma, Toxicity, medicine, Clinical endpoint, Vomiting, medicine.symptom, business, Adverse effect

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::35671dd0c8c34b1c3b64f763202167d7Test
https://doi.org/10.1158/1535-7163.targ-11-b56Test

103

Abstract B128: A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: Interim results

المؤلفون: Anthony W. Tolcher, Howard A. Burris, Kevin M. Bellew, Amita Patnaik, Ngocdiep T. Le, Johanna C. Bendell, Suzanne F. Jones, Kiriakos P. Papadopoulos, Jeffrey R. Infante, Michael Durante, Drew W. Rasco, Donna S. Cox, Joohyun Jennifer Park

المصدر: Molecular Cancer Therapeutics. 10:B128-B128

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Everolimus, business.industry, Cancer, Pharmacology, medicine.disease, Gastroenterology, Hypokalemia, Regimen, Oncology, Pharmacokinetics, Tolerability, Internal medicine, Pancreatic cancer, medicine, medicine.symptom, business, Adverse effect, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::5be84a59f11b0a7da2504ccf5a3789cbTest
https://doi.org/10.1158/1535-7163.targ-11-b128Test

104

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)

المصدر: Journal of Clinical Oncology. 29:CRA8503-CRA8503

مصطلحات موضوعية: Drug, BRAF Inhibitor GSK2118436, Cancer Research, business.industry, media_common.quotation_subject, MEK inhibitor, Melanoma, Pharmacology, medicine.disease, Salivary duct carcinoma, Oncology, Pharmacokinetics, Cancer cell, Medicine, Dosing, business, media_common

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1d7a2c108b6ac92f6d09a38e91e14f30Test
https://doi.org/10.1200/jco.2011.29.18_suppl.cra8503Test

105

A phase I dose-escalation and pharmacokinetic (PK) evaluation of an oral AKT inhibitor, LY2503029 (LY)

المؤلفون: Les H. Brail, I. Gueorguieva, J. R. Infante, Johanna C. Bendell, D. Satonin, A. P. Anderson, Steven J.M. Jones, S. A. Limentani, H. A. Burris

المصدر: Journal of Clinical Oncology. 29:e13575-e13575

مصطلحات موضوعية: Cancer Research, business.industry, Cancer, Pharmacology, medicine.disease, Metastasis, Oncolytic virus, Oncology, Pharmacokinetics, In vivo, Vomiting, Medicine, medicine.symptom, business, Protein kinase B, PI3K/AKT/mTOR pathway

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::5a0452452632a40c4c8c22f6e7953fdfTest
https://doi.org/10.1200/jco.2011.29.15_suppl.e13575Test

106

A phase I dose-escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment

المؤلفون: D. D. Von Hoff, R. K. Ramanathan, Natalie R. Dickson, H. A. Burris, J. R. Infante, Johanna C. Bendell, Glen J. Weiss, William McCulloch, Siân Jones

المصدر: Journal of Clinical Oncology. 29:2607-2607

مصطلحات موضوعية: chemistry.chemical_classification, Cancer Research, business.industry, Regulator, Pharmacology, Oncology, Refractory, chemistry, Transferrin, Dose escalation, Medicine, In patient, business, Intracellular

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::d7877c6b1cea8a342c39a14b1201a0afTest
https://doi.org/10.1200/jco.2011.29.15_suppl.2607Test

107

A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors

المؤلفون: H. A. Burris, F. C. Lee, Robert C. Newton, Siân Jones, J. Boer, Johanna C. Bendell, Xuesong Mike Liu, T. Gau, Ross C. Donehower, M. Hill, Qiang Wang, Peggy Scherle, J. D. Bowman, J. R. Infante, S. Diamond, A. Scardina

المصدر: Journal of Clinical Oncology. 29:3091-3091

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, biology, business.industry, Pharmacology, medicine.disease, Receptor tyrosine kinase, Breast cancer, medicine.anatomical_structure, Pharmacokinetics, Prostate, Pharmacodynamics, Internal medicine, Cancer cell, biology.protein, Medicine, In patient, business, Whole blood

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::6fc84643a2fbd02c3cace92f86f3a3c8Test
https://doi.org/10.1200/jco.2011.29.15_suppl.3091Test

108

A phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administered either on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim (peg) every 21 days (NCT01214642)

المؤلفون: J. R. Infante, A.E. McGlothlin, H. A. Burris, Kyri Papadopoulos, Muralidhar Beeram, J. Leohr, Aejaz Nasir, Scott M. Hynes, Daphne L. Farrington, Amita Patnaik, Johanna C. Bendell, Rebecca Arcos, Kent C. Shih, Anthony W. Tolcher, J. T. Brandt, L. Jackson, Eric H. Westin

المصدر: Journal of Clinical Oncology. 29:2600-2600

مصطلحات موضوعية: Cancer Research, Oncology, business.industry, Phase (matter), Allosteric regulation, PEG ratio, Dose escalation, Medicine, Pharmacology, business, Pegfilgrastim, medicine.drug, Spindle apparatus

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::d1b9bcaeb40b5a6e9e8d3eef860bafe0Test
https://doi.org/10.1200/jco.2011.29.15_suppl.2600Test

109

A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors

المؤلفون: Andrew J. Wagner, Jennifer O. Lauchle, Howard A. Burris, K. E. Mazina, Johanna C. Bendell, Joseph A. Ware, J.S. de Bono, Jeffrey A. Morgan, Saoirse Dolly, Jill Fredrickson

المصدر: Journal of Clinical Oncology. 29:3020-3020

مصطلحات موضوعية: Cancer Research, business.industry, Cancer, Pharmacology, P110α, medicine.disease, medicine.anatomical_structure, Oncology, Pharmacokinetics, Prostate, Pharmacodynamics, medicine, Avidity, business, IC50, PI3K/AKT/mTOR pathway

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::7bee236256241966ef7b9c1ce5906118Test
https://doi.org/10.1200/jco.2011.29.15_suppl.3020Test

110

Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors

المؤلفون: A. de Crespigny, James M. Cleary, Mary Gates, Marcia Belvin, Geoffrey I. Shapiro, Iris T. Chan, Luna Musib, Cheryl Jones, E. L. Kwak, Meghan McKenzie, Johanna C. Bendell, Patricia LoRusso

المصدر: Journal of Clinical Oncology. 29:3005-3005

مصطلحات موضوعية: Cancer Research, Schedule, business.industry, Pharmacology, Intermittent dosing, Oncology, Pharmacokinetics, Medicine, In patient, Dosing, business, Protein kinase B, MEK Inhibitor GDC-0973, PI3K/AKT/mTOR pathway

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::f7d05f21ea1fd761d89ee341cfa4a7f1Test
https://doi.org/10.1200/jco.2011.29.15_suppl.3005Test

تنقيح النتائج